The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization.

Autor: Pipa-Muñiz M; Division of Gastroenterology and Hepatology, Hospital de Cabueñes, Gijón, Spain., Sanmartino S; Radiology Department, Hospital Universitario Central de Asturias, Oviedo, Spain., Mesa A; Radiology Department, Hospital Universitario Central de Asturias, Oviedo, Spain., Álvarez-Navascués C; Liver Unit, Hospital Universitario Central de Asturias, 33011, Oviedo, Spain., González-Diéguez ML; Liver Unit, Hospital Universitario Central de Asturias, 33011, Oviedo, Spain., Cadahía V; Liver Unit, Hospital Universitario Central de Asturias, 33011, Oviedo, Spain., Rodríguez JE; Radiology Department, Hospital Universitario Central de Asturias, Oviedo, Spain., Vega F; Radiology Department, Hospital Universitario Central de Asturias, Oviedo, Spain., Rodríguez M; Liver Unit, Hospital Universitario Central de Asturias, 33011, Oviedo, Spain.; Universidad de Oviedo, Oviedo, Spain., Costilla-García SM; Radiology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.; Universidad de Oviedo, Oviedo, Spain., Varela M; Liver Unit, Hospital Universitario Central de Asturias, 33011, Oviedo, Spain. maria.varela.calvo@gmail.com.
Jazyk: angličtina
Zdroj: BMC gastroenterology [BMC Gastroenterol] 2020 Jun 01; Vol. 20 (1), pp. 166. Date of Electronic Publication: 2020 Jun 01.
DOI: 10.1186/s12876-020-01307-x
Abstrakt: Background: A single-centre cohort study was performed to identify the independent factors associated with the overall survival (OS) of hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization with drug-eluting beads (DEB-TACE).
Methods: A total of 216 HCC patients who underwent DEB-TACE from October 2008 to October 2015 at a tertiary hospital were consecutively recruited. The analysis of prognostic factors associated with overall survival after DEB-TACE, stressing the role of post-TACE events, was performed.
Results: The objective response (OR) rate (Modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria) to the first DEB-TACE (DEB-TACE-1) was 70.3%; the median OS from DEB-TACE-1 was 27 months (95% confidence interval (CI), 24-30). In the multivariate analysis, tumor size, AFP < 100 ng/mL and serum alkaline phosphatase were independent factors for survival following DEB-TACE-1. The most important clinical event associated with poor survival was the development of early ascites after DEB-TACE-1 (median OS, 17 months), which was closely related to the history of ascites, albumin and hemoglobin but not to tumour load or to response to therapy.
Conclusions: Early ascites post-DEB-TACE is associated with the survival of patients despite adequate liver function and the use of a supra-selective technical approach. History of ascites, albumin and hemoglobin are major determinants of the development of early ascites post-DEB-TACE.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje